Work

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

Year: 2019

Type: review

Abstract: In non-small cell lung cancer (NSCLC), the most frequent oncogenic mutation in western countries is KRAS, which, however, remains no clinically approved targeted therapies. Recent progress on high biological heterogeneity including diverse KRAS point mutations, varying dependence on mutant KRAS, wide spectrum of other co-occurring genetic alterations, as well as distinct cellular status across the epithelial-to-mesenchymal transition (EMT), has not only deepened our understanding about the pathobiology of KRAS-mutant NSCLC, but also brought about unprecedented new hopes for precision treatment of patients. In this review, we update most recent advances in KRAS-mutant lung cancer, with a focus on mechanistic insights into tumor heterogeneity, the potential clinic implications and new therapies on horizons tailored for KRAS-mutant lung cancer.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2019.00953

Authors: Haitang Yang, Shun-Qing Liang, Ralph A. Schmid, Ren-Wang Peng

Institutions: University of Bern, University Hospital of Bern, University of Massachusetts Chan Medical School

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490